Hematologic Oncology | Specialty

Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014

Discontinuation of Treatment With TKIs in CML

January 9th 2014

Introduction: Treatment Landscape of MDS

January 9th 2014

Dr. Tallman on BRAF Inhibitors for the Treatment of HCL

January 8th 2014

Martin S. Tallman, MD, Chief, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of hairy cell leukemia (HCL) with a BRAF inhibitor.

Brentuximab Vedotin Should Not Be Combined With Bleomycin in First-Line Treatment of Hodgkin Lymphoma

January 8th 2014

Brentuximab vedotin (Adcetris) should not be given with bleomycin as a first-line therapy for patients with advanced-stage Hodgkin lymphoma

Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments

January 2nd 2014

Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers.

Dr. Pierluigi Porcu Discusses CTCL Research

December 30th 2013

Pierluigi Porcu, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), discusses early research in CTCL.

Dr. Padron on the SRSF2 Mutation in MDS and CMML

December 23rd 2013

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Dr. Shapiro Discusses Bosutinib in CML

December 23rd 2013

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Dr. Pardee Provides an Update on CPI-613

December 20th 2013

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Caligiuri on the Anti-KIR Antibody IPH2101

December 19th 2013

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas

December 19th 2013

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Dr. Amengual on Vorinostat and Niacinamide in Lymphoma

December 19th 2013

Jennifer E. Amengual, MD, assistant professor of medicine and developmental therapeutics, member, Center for Lymphoid Malignancies, Columbia University, discusses the potential of the combination of vorinostat and niacinamide as treatment for patients with diffuse large B-cell lymphoma.

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

December 16th 2013

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

Idelalisib Improves Survival in High-Risk CLL

December 13th 2013

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

Quizartinib Active in AML at Lower Doses

December 13th 2013

Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.

Dr. Goy on CAR-Modified T Cells in Lymphoma

December 13th 2013

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Latest Data Further Support Ibrutinib's Efficacy in CLL

December 11th 2013

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Dr. Furman on Avoiding Chemotherapy With Idelalisib

December 10th 2013

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.